Teva Pharmaceutical Industries (TEVA) US affiliate and Alvotech (ALVO) said Friday that the Selarsdi injection is now available in the US to treat psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis.
Selarsdi is biosimilar to Stelara and it is the second biosimilar now available in the country under the Teva and Alvotech collaboration, they added.
The US Food and Drug Administration provisionally determined that Selarsdi is interchangeable with the reference biologic Stelara after the first interchangeable biosimilar expires, on April 30, the parties said.
Teva Pharmaceutical's stock rose 2.7%, while Alvotech's shares were up 3% in recent Friday premarket activity.
Price: 17.46, Change: +0.46, Percent Change: +2.71
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。